View Older Stories View More Recent Stories

May 30, 2025 09:44AM BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
May 28, 2025 08:31AM Halozyme Therapeutics (HALO) Announces Bristol Myers Squibb (BMY) Received European Commission Approval for Subcutaneous Opdivo Co-Formulated with ENHANZE
May 28, 2025 06:56AM Bristol-Myers Squibb (BMY) Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
May 24, 2025 10:00PM What can get the U.S. large-cap pharma sector to work?
May 23, 2025 01:23PM RayJay on Veeva (VEEV): 'we haven’t heard any official designation on Bristol-Myers Squib’s plans for CRM going forward, our understanding is that CRM add-ons won’t be portable to Salesforce'
May 22, 2025 05:28PM Bristol-Myers Squibb (BMY) to present data on oncology portfolio and pipeline at ASCO 2025
May 16, 2025 07:00AM Bristol-Myers Squibb (BMY) Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo
May 7, 2025 04:32PM Trump to pitch sweeping Medicare drug price plan - Politico
May 7, 2025 05:28AM Bristol-Myers Squibb (BMY) call put ratio 1 call to 1.5 puts
May 6, 2025 06:59AM Bristol-Myers Squibb (BMY) Appoints Cari Gallman as Chief Policy Officer
Apr 25, 2025 08:46AM Bristol-Myers Squibb Co. (BMY) PT Raised to $56 at BofA Securities
Apr 24, 2025 07:01AM Bristol-Myers Squibb (BMY) Tops Q1 EPS by 28c ; Offers Guidance
Apr 23, 2025 03:09PM Bristol-Myers Squibb (BMY) call put ratio 1 call to 1.2 puts on 38K contracts into quarter results
Apr 23, 2025 09:20AM BMO Capital on Bristol-Myers Squibb Co. (BMY): 'ARISE Trial Miss Adds to More Difficult Story'
Apr 23, 2025 09:04AM Truist on Bristol-Myers Squibb Co. (BMY): 'Cobenfy Failure in ARISE Likely to Pressure Shares'
Apr 23, 2025 05:23AM Bristol-Myers Squibb Co. (BMY) PT Lowered to $68 at Jefferies
Apr 22, 2025 04:40PM After-hours movers: Tesla, Oklo, Intuitive Surgical and more
Apr 22, 2025 04:20PM Bristol-Myers Squibb (BMY) Phase 3 ARISE Trial Evaluating Cobenfy as Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia Did Not Reach Threshold
Apr 22, 2025 07:20AM Cantor Fitzgerald Starts Bristol-Myers Squibb Co. (BMY) at Neutral
Apr 21, 2025 05:31PM Piper Sandler Starts Bristol-Myers Squibb Co. (BMY) at Overweight
Apr 21, 2025 06:35AM Goldman Sachs Reiterates Neutral Rating on Bristol-Myers Squibb Co. (BMY)
Apr 15, 2025 08:37AM BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
Apr 14, 2025 04:15PM Bristol-Myers Squibb (BMY) Provides Update on Phase 3 ODYSSEY-HCM Trial
Apr 11, 2025 03:49PM Bristol-Myers Squibb (BMY): FDA Approves Opdivo plus Yervoy as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
Apr 11, 2025 10:08AM Bristol-Myers Squibb Co. (BMY) PT Lowered to $54 at UBS
Apr 9, 2025 09:19AM Pharma stocks slide after Trump signals tariffs on sector
Apr 8, 2025 03:39PM Bristol-Myers Squibb (BMY): FDA Approves Opdivo plus Yervoy as Treatment for Patients with Previously Untreated MSI-H or dMMR
Apr 8, 2025 01:27PM FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or DMMR Colorectal Cancer
Apr 8, 2025 05:09AM Goldman Sachs Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral
Apr 7, 2025 11:47AM BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
Apr 4, 2025 05:26AM BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
Apr 1, 2025 09:33AM Bernstein Assesses U.S. Biopharma Stocks Amid Tariff Risks
Mar 31, 2025 08:10AM BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
Mar 28, 2025 08:55AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo
Mar 28, 2025 08:00AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo
Mar 27, 2025 09:44AM UBS Reiterates Neutral Rating on Bristol-Myers Squibb Co. (BMY)
Mar 15, 2025 04:00PM Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
Mar 15, 2025 04:00AM How could tariffs shake up the pharma sector?
Mar 14, 2025 06:59AM Bristol-Myers Squibb (BMY) Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi
Mar 10, 2025 10:17PM 2seventy bio (TSVT) Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
Mar 7, 2025 06:59AM Bristol-Myers Squibb (BMY) Receives European Commission Approval for Opdivo plus Yervoy for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
Mar 4, 2025 01:45AM Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
Mar 3, 2025 04:16PM Bristol-Myers Squibb (BMY) Declares $0.62 Quarterly Dividend; 4.1% Yield
Feb 24, 2025 06:59AM Bristol-Myers Squibb (BMY) Announces FDA Acceptance of Supplemental Biologics License Application for Opdivo Plus Yervoy
Feb 19, 2025 07:00AM Bristol-Myers Squibb (BMY) Announces Opdivo Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall
Feb 13, 2025 04:16PM Bristol-Myers Squibb (BMY) Reports Phase 3 RELATIVITY-098 Trial Did Not Meet Endpoint
Feb 10, 2025 06:59AM Bristol-Myers Squibb (BMY) Reports Positive Topline Results for Breyanzi
Feb 7, 2025 07:48AM Bristol-Myers Squibb Co. (BMY) PT Raised to $67 at Goldman Sachs
Feb 6, 2025 07:00AM Bristol-Myers Squibb (BMY) Tops Q4 EPS by 20c; guides below consensus
Feb 5, 2025 11:05AM Bristol-Myers Squibb (BMY) call put ratio 9.2 calls to 1 put with a focus on May 16.50 calls into quarter results
View More Recent Stories View Older Stories